促红细胞生成素作为脓毒症ICU患者关键预后指标的前瞻性观察研究
该前瞻性观察研究纳入267例脓毒症患者(男性65.17%),按促红细胞生成素三分位分组,主要终点为28天死亡率。28天死亡率为23.22%,住院死亡率为31.20%。多因素Cox回归显示,促红细胞生成素最高三分位组28天死亡风险(HR 2.93,95%CI 1.20-7.22)和住院死亡风险(HR 2.47,95%CI 1.05-5.81)均显著高于最低三分位组。限制性立方样条显示促红细胞生成素水平升高与死亡风险递增相关。因果中介分析显示,乳酸与28天死亡率之间的关联部分由促红细胞生成素中介,中介比例为12.59%。
要点
- 脓毒症患者按促红细胞生成素三分位分组,最高三分位组28天死亡风险显著高于最低三分位组(HR 2.93,95%CI 1.20-7.22)。
- 最高三分位组住院死亡风险也显著高于最低三分位组(HR 2.47,95%CI 1.05-5.81)。
- 限制性立方样条分析显示,促红细胞生成素水平升高与死亡风险递增相关。
- 乳酸与28天死亡率之间的关联部分由促红细胞生成素中介,中介比例为12.59%。
- 亚组分析证实效应量和方向在不同亚组间一致且稳定。
适用人群与场景
- ICU脓毒症患者,共267例,男性65.17%。
研究设计与关键结果
- 研究类型为前瞻性观察研究,纳入267例脓毒症患者(男性65.17%),按促红细胞生成素三分位分为三组,主要终点为28天死亡率。
- 28天死亡率为23.22%,住院死亡率为31.20%。
- 多因素Cox回归显示,促红细胞生成素最高三分位组较低三分位组28天死亡风险显著升高(HR 2.93,95%CI 1.20-7.22),住院死亡风险也显著升高(HR 2.47,95%CI 1.05-5.81)。
- 限制性立方样条分析显示,促红细胞生成素水平升高与死亡风险递增相关。
- 亚组分析证实效应量和方向在不同亚组间一致且稳定。
- 因果中介分析显示,乳酸与28天死亡率之间的关联部分由促红细胞生成素中介,中介比例为12.59%。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症患者促红细胞生成素水平升高与不良预后相关,可能作为不良结局的预后生物标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Erythropoietin (EPO), a glycoprotein hormone primarily produced in the kidneys, plays pleiotropic roles in hematopoietic and non-hematopoietic system. However, the clinical relevance of circulating EPO in sepsis progression and outcomes remains contentious and requires further elucidation.
METHODS: Participants were categorized into three groups on the basis of EPO tertiles. The primary outcome was 28-day mortality. Multivariate Cox proportional regression analysis and restricted cubic spline regression were employed to evaluate the association between EPO levels and 28-day mortality in sepsis patients. Subgroup analyses were also conducted. Causal mediation analysis was conducted to explore the potential mediating role of EPO in the relationship between lactate and 28-day mortality.
RESULTS: A total of 267 patients (65.17% male) were included in the study. The 28-day and hospital mortality rates were 23.22 and 31.20%, respectively. Multivariate Cox regression revealed significantly higher 28-day and hospital mortality in the highest EPO tertile compared to the lowest (HR 2.93, 95% CI 1.20-7.22; HR 2.47, 95% CI 1.05-5.81, respectively). Restricted cubic spline analysis demonstrated a progressively increasing mortality risk with elevated EPO levels. Subgroup analyses confirmed the consistency and stability of the effect size and direction across different subgroups. Moreover, causal intermediary analysis revealed that the association between lactate and 28-day mortality was partially mediated by EPO, with a mediation ratio of 12.59%.
CONCLUSIONS: Elevated EPO levels in patients with sepsis are correlated with unfavorable prognoses and may function as a prognostic biomarker for adverse outcomes.
参考来源
- Zhang Q, Zhang Y, Tian X, et al. Erythropoietin as a critical prognostic indicator in ICU patients with sepsis: a prospective observational study. J Intensive Care. 2025. PMID: 40114237. doi:10.1186/s40560-025-00787-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。